LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Your last searches

  1. AU="Vandeloo, Judith"
  2. AU="Meyers, Amanda"
  3. AU="Jiménez-Bambague, Eliana M"
  4. AU="Turner, J C"
  5. AU="Moore, C J" AU="Moore, C J"
  6. AU="Leresche, Téa"
  7. AU=Astrom Siv AU=Astrom Siv
  8. AU="Di Meglio, Florent"
  9. AU=Simon H U
  10. AU=Croucher P I
  11. AU="Jasti, Madhu"

Search results

Result 1 - 3 of total 3

Search options

  1. Article ; Online: Hepatitis B virus prevalence in first-time blood donors in Flanders, Belgium: Impact of universal vaccination and migration.

    De Brier, Niels / Koc, Özgür M / De Buck, Emmy / Muylaert, An / Nevens, Frederik / Vanbrabant, Miek / Vandeloo, Judith / Van Remoortel, Hans / Robaeys, Geert / Compernolle, Veerle

    Transfusion

    2021  Volume 61, Issue 7, Page(s) 2125–2136

    Abstract: Background: Transfusion-transmissible infections such as hepatitis B virus (HBV) remain a major concern for the safety of blood transfusion. This cross-sectional study aimed to assess the trend of HBV prevalence and associated risk factors among a first- ...

    Abstract Background: Transfusion-transmissible infections such as hepatitis B virus (HBV) remain a major concern for the safety of blood transfusion. This cross-sectional study aimed to assess the trend of HBV prevalence and associated risk factors among a first-time donor population in a low endemic country.
    Study design and methods: Between 2010 and 2018, blood samples were collected from first-time donors presented at donor collection sites of Belgian Red Cross-Flanders. They were tested for hepatitis B surface antigen (HBsAg), hepatitis B core antibodies (anti-HBc), and HBV DNA, HIV and hepatitis virus C (HCV) antibodies and RNA, and syphilis antibodies.
    Results: A total of 211,331 first-time blood donors (43.7% males, median age 25 years) were analyzed. HBsAg prevalence decreased from 0.06% in 2010 to 0.05% in 2018 (p = .004) and this declining trend was accompanied by an increased number of donors in the HBV vaccinated birth cohort (p < .001). HBsAg prevalence was 0.33% in foreign-born donors and 0.02% in Belgian natives (p < .001). Multivariate risk profiling showed that anti-HBc positivity was significantly associated with mainly foreign-born donors (odds ratio [OR] = 9.24) but also with older age (OR = 1.06), male gender (OR = 1.32), year of blood donation (OR = 0.94), and co-infections with HCV (OR = 4.31) or syphilis (OR = 4.91).
    Discussion: The decreasing trend in HBV prevalence could mainly be explained by the introduction of the universal HBV vaccination. Being born in endemic areas was the most important predictor for HBV infection while the co-infections with syphilis suggest unreported sexual risk contacts.
    MeSH term(s) Adolescent ; Adult ; Age Factors ; Belgium/epidemiology ; Blood Donors ; Cross-Sectional Studies ; Emigrants and Immigrants/statistics & numerical data ; Female ; Hepatitis B/blood ; Hepatitis B/epidemiology ; Hepatitis B Antibodies/blood ; Hepatitis B Core Antigens/immunology ; Hepatitis B Surface Antigens/blood ; Hepatitis B Vaccines ; Hepatitis B virus/isolation & purification ; Humans ; Male ; Middle Aged ; Prevalence ; Risk Factors ; Sex Factors ; Transfusion Reaction/prevention & control ; Urban Population ; Vaccination ; Viremia/blood ; Viremia/epidemiology ; Young Adult
    Chemical Substances Hepatitis B Antibodies ; Hepatitis B Core Antigens ; Hepatitis B Surface Antigens ; Hepatitis B Vaccines
    Language English
    Publishing date 2021-05-06
    Publishing country United States
    Document type Journal Article ; Multicenter Study ; Research Support, Non-U.S. Gov't
    ZDB-ID 208417-x
    ISSN 1537-2995 ; 0041-1132
    ISSN (online) 1537-2995
    ISSN 0041-1132
    DOI 10.1111/trf.16431
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Therapeutic vaccination with an autologous mRNA electroporated dendritic cell vaccine in patients with advanced melanoma.

    Wilgenhof, Sofie / Van Nuffel, An M T / Corthals, Jurgen / Heirman, Carlo / Tuyaerts, Sandra / Benteyn, Daphné / De Coninck, Arlette / Van Riet, Ivan / Verfaillie, Guy / Vandeloo, Judith / Bonehill, Aude / Thielemans, Kris / Neyns, Bart

    Journal of immunotherapy (Hagerstown, Md. : 1997)

    2011  Volume 34, Issue 5, Page(s) 448–456

    Abstract: The immunostimulatory capacity of dendritic cells is improved by co-electroporation with mRNA encoding CD40 ligand, constitutively active toll-like receptor 4, and CD70 (TriMix-DC). This pilot clinical trial evaluated the feasibility, safety, and ... ...

    Abstract The immunostimulatory capacity of dendritic cells is improved by co-electroporation with mRNA encoding CD40 ligand, constitutively active toll-like receptor 4, and CD70 (TriMix-DC). This pilot clinical trial evaluated the feasibility, safety, and immunogenicity of a therapeutic vaccination containing autologous TriMix-DC co-electroporated with mRNA encoding a human leukocyte antigen class II-targeting signal linked to 1 of 4 melanoma-associated antigens (MAGE-A3, MAGE-C2, tyrosinase, and gp100) in patients with advanced melanoma. Thirty-five American Joint Committee on Cancer stage III/IV melanoma patients received autologous TriMix-DC (4 administrations 2 weeks apart). Immune monitoring was performed by evaluating skin biopsies of delayed type IV hypersensitivity (DTH) reactions for presence of vaccinal antigen-specific DTH-infiltrating lymphocytes (DIL). Thereafter, patients could receive interferon-alpha-2b (IFN-α-2b) 5 MU subcutaneously 3 times weekly and additional TriMix-DC every 8 weeks. TriMix-DC-related adverse events comprised grade 2 local injection site reactions (all patients), and grade 2 fever and lethargy (2 patients). Vaccinal antigen-specific DIL were found in 0/6 patients tested at vaccine initiation and in 12/21 (57.1%) assessed after the fourth vaccine. A positive postvaccination DTH test correlated with IL-12p70 secretion capacity of TriMix-DC. No objective responses to TriMix-DC alone were seen according to RECIST. Twenty-nine patients received IFN-α-2b after the fourth vaccine without unexpected adverse events. During TriMix-DC/IFN-α-2b combination therapy, 1 partial response and 5 stable disease (disease control of >6 months with regression of metastases) were observed in 17 patients with evaluable disease at baseline. In conclusion, this study demonstrated that therapeutic vaccination with autologous TriMix-DC is feasible, safe, and immunogenic and can be combined with sequential IFN-α-2b.
    MeSH term(s) Adult ; Aged ; Antigens, Neoplasm/immunology ; CD27 Ligand/immunology ; CD27 Ligand/metabolism ; CD40 Antigens/immunology ; CD40 Antigens/metabolism ; Cancer Vaccines/administration & dosage ; Cancer Vaccines/immunology ; Dendritic Cells/cytology ; Dendritic Cells/immunology ; Dendritic Cells/metabolism ; Drug Therapy, Combination/methods ; Electroporation ; Female ; Histocompatibility Antigens Class II/immunology ; Histocompatibility Antigens Class II/metabolism ; Humans ; Hypersensitivity, Delayed/immunology ; Interferon-alpha/administration & dosage ; Male ; Melanoma ; Middle Aged ; Neoplasm Staging ; RNA, Messenger/immunology ; RNA, Messenger/metabolism ; Recombinant Proteins ; Skin Neoplasms/drug therapy ; Skin Neoplasms/immunology ; Skin Neoplasms/mortality ; Skin Neoplasms/pathology ; Survival Analysis ; Toll-Like Receptor 4/immunology ; Toll-Like Receptor 4/metabolism ; Vaccination
    Chemical Substances Antigens, Neoplasm ; CD27 Ligand ; CD40 Antigens ; Cancer Vaccines ; Histocompatibility Antigens Class II ; Interferon-alpha ; RNA, Messenger ; Recombinant Proteins ; TLR4 protein, human ; Toll-Like Receptor 4 ; interferon alfa-2b (43K1W2T1M6)
    Language English
    Publishing date 2011-06
    Publishing country United States
    Document type Clinical Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1064067-8
    ISSN 1537-4513 ; 1053-8550 ; 1524-9557
    ISSN (online) 1537-4513
    ISSN 1053-8550 ; 1524-9557
    DOI 10.1097/CJI.0b013e31821dcb31
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: A phase I/IIa immunotherapy trial of HIV-1-infected patients with Tat, Rev and Nef expressing dendritic cells followed by treatment interruption.

    Allard, Sabine D / De Keersmaecker, Brenda / de Goede, Anna L / Verschuren, Esther J / Koetsveld, Jeanette / Reedijk, Mariska L / Wylock, Carolien / De Bel, Annelies V / Vandeloo, Judith / Pistoor, Frank / Heirman, Carlo / Beyer, Walter E P / Eilers, Paul H C / Corthals, Jurgen / Padmos, Iman / Thielemans, Kris / Osterhaus, Albert D M E / Lacor, Patrick / van der Ende, Marchina E /
    Aerts, Joeri L / van Baalen, Carel A / Gruters, Rob A

    Clinical immunology (Orlando, Fla.)

    2012  Volume 142, Issue 3, Page(s) 252–268

    Abstract: In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4 vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev and Nef, after which cART was interrupted. Vaccination was safe and feasible. ... ...

    Abstract In a phase I/IIa clinical trial, 17 HIV-1 infected patients, stable on cART, received 4 vaccinations with autologous dendritic cells electroporated with mRNA encoding Tat, Rev and Nef, after which cART was interrupted. Vaccination was safe and feasible. During the analytical treatment interruption (ATI), no serious adverse events were observed. Ninety-six weeks following ATI, 6/17 patients remained off therapy. Although induced and/or enhanced CD4(+) and CD8(+) T-cell responses specific for the immunogens were observed in most of the patients, we found no correlation with the number of weeks off cART. Moreover, CD4(+) T-cell counts, plasma viral load and the time remaining off cART following ATI did not differ from historical control data. To conclude, the vaccine was safe, well tolerated and resulted in vaccine-specific immune responses. Since no correlation with clinical parameters could be found, these results warrant further research in order to optimize the efficacy of vaccine-induced T-cell responses.
    MeSH term(s) AIDS Vaccines/immunology ; Adult ; Aged ; Cells, Cultured ; Dendritic Cells/immunology ; Gene Products, rev/immunology ; Gene Products, tat/immunology ; HIV Infections/immunology ; HIV Infections/therapy ; HIV-1/immunology ; Humans ; Immunization ; Male ; Middle Aged ; nef Gene Products, Human Immunodeficiency Virus/immunology
    Chemical Substances AIDS Vaccines ; Gene Products, rev ; Gene Products, tat ; nef Gene Products, Human Immunodeficiency Virus
    Language English
    Publishing date 2012-03
    Publishing country United States
    Document type Clinical Trial, Phase I ; Clinical Trial, Phase II ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 1459903-x
    ISSN 1521-7035 ; 1521-6616
    ISSN (online) 1521-7035
    ISSN 1521-6616
    DOI 10.1016/j.clim.2011.10.010
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top